New York State Common Retirement Fund Sells 39,010 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

New York State Common Retirement Fund lowered its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 7.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 476,338 shares of the company’s stock after selling 39,010 shares during the quarter. New York State Common Retirement Fund owned approximately 0.39% of 10x Genomics worth $6,840,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Creative Planning bought a new stake in 10x Genomics in the 3rd quarter valued at $214,000. Blue Trust Inc. boosted its holdings in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after purchasing an additional 1,025 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of 10x Genomics by 2,280.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 38,963 shares of the company’s stock valued at $880,000 after purchasing an additional 37,326 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of 10x Genomics in the third quarter worth about $438,000. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of 10x Genomics by 84.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 23,952 shares of the company’s stock worth $541,000 after purchasing an additional 10,935 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Insiders Place Their Bets

In other news, Director Alan Mateo purchased 40,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were purchased at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the purchase, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. This represents a 184.41 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $11.65 on Thursday. 10x Genomics, Inc. has a fifty-two week low of $10.63 and a fifty-two week high of $48.42. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -7.66 and a beta of 1.85. The business’s 50 day moving average price is $14.13 and its 200-day moving average price is $16.92.

10x Genomics (NASDAQ:TXG) last released its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Sell-side analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TXG shares. Barclays cut their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Monday, February 10th. UBS Group cut their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Morgan Stanley decreased their price target on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Canaccord Genuity Group dropped their price objective on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Leerink Partnrs downgraded shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, 10x Genomics currently has an average rating of “Hold” and a consensus target price of $20.57.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.